Novo Nordisk A/S $NVO Shares Bought by Korea Investment CORP

Korea Investment CORP grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 98.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,140 shares of the company’s stock after purchasing an additional 37,748 shares during the quarter. Korea Investment CORP’s holdings in Novo Nordisk A/S were worth $4,225,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in NVO. True Wealth Design LLC increased its holdings in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the last quarter. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S during the third quarter worth $25,000. Strengthening Families & Communities LLC acquired a new position in Novo Nordisk A/S during the third quarter worth $30,000. Allianz SE grew its holdings in Novo Nordisk A/S by 70.0% in the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after buying an additional 238 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth $39,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $38.04 on Friday. The stock has a fifty day simple moving average of $50.43 and a 200-day simple moving average of $51.92. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The stock has a market cap of $169.83 billion, a PE ratio of 10.96 and a beta of 0.73. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $82.57.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is 23.63%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on NVO. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a research note on Tuesday. Citigroup assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Finally, Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Four analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $49.93.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Zacks upgraded Novo Nordisk from “strong sell” to “hold,” a modest vote that may limit further downside from some retail/quant sellers. Read More.
• Positive Sentiment: Novo entered a WHO Foundation partnership focused on cardio‑renal‑metabolic diseases and committed funding for obesity/diabetes efforts in low‑ and middle‑income countries — a reputational and long‑term access play that supports the company’s global public‑health positioning. Read More.
• Neutral Sentiment: Novo Holdings published 2025 annual results showing income and investment returns; while the report is routine, its figures are being viewed through the lens of Novo Nordisk’s share‑price swing. Read More.
• Neutral Sentiment: India’s regulator warned drugmakers about direct or surrogate advertising for weight‑loss drugs, a policy development that adds regulatory complexity across a large and fast‑growing market but is industry‑wide rather than Novo‑specific. Read More.
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide, triggering immediate regulatory risk and heightened compliance scrutiny that can hurt investor confidence and valuation. Read More.
• Negative Sentiment: Regulatory news sparked sharp market reaction and legal attention: a class‑action/investor probe (Pomerantz) was announced and some articles report a very steep intraday drop tied to the FDA news, increasing the chance of litigation and reputational/financial fallout. Read More.
• Negative Sentiment: Analysts have reacted: TD Cowen and others trimmed ratings/targets, and coverage notes the hit to Novo Holdings’ controlling‑shareholder asset value — both amplify selling pressure. Read More.
• Negative Sentiment: Competitive pressure from Eli Lilly (big investments and programs to expand GLP‑1 access) is a strategic negative for Novo’s long‑term market share and pricing power in GLP‑1s. Investors should factor stronger Lilly initiatives into longer‑term growth forecasts. Read More.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.